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Summary The changes in the phosphorus metabolism of a xenografted hypopharynx carcinoma (Hyp 1),
sensitive to cisplatin (CDDP), were compared to those occurring in two sublines of the tumour, characterised
by moderate or high resistance to CDDP (Hyp 1/H and Hyp I/R) following, i.p. administration of 4, 8 or
12 mg CDDP/kg-. The investigations were performed by in vivo 31P nuclear magnetic resonance (NMR)
spectroscopy. Parallel to the NMR experiments, the cytokinetic and histological alterations in the tumours
were studied under the same experimental conditions. No mentionable differences in the levels of the main
phosphorus-containing metabolites could be detected between the three tumour lines before treatment.
Following application of CDDP, the alterations in the NMR spectra were clearly related to the degree of
tumour response. The most sensitive and earliest marker of tumour regression was a decrease in the
phosphomonoester/phosphodiester ratio, parallelled by a gradual increase in the phosphocreatine/inorganic
phosphorus quotient. In the resistant tumour lines Hyp 1/H and Hyp 1/R non-responding tumours showed
alterations in the 31P NMR spectrum which were similar to those observed during uninfluenced tumour
growth. Marked changes in the 31P NMR spectrum were always associated with severe cytotoxic lesions
following therapy. The results suggest that the changes detected by 31P NMR spectroscopy following
chemotherapy with CDDP are response-specific.
In vivo 31P NMR spectroscopy is a recently developed,
clinically applicable technique that provides a non-invasive
monitor of pH and phosphorus-containing metabolites which
are either involved in energy metabolism, such as phospho-
creatine (PCr), nucleosidetriphosphates (NTP:) and inorganic
phosphorus (Pi), or in lipid metabolism, such as phospho-
monoesters (PME) and phosphodiesters (PDE) (for an over-
view see Glickson, 1989). Some previous studies revealed that
administration of chemotherapy was often accompanied by
reenergisation of the tumours, whilst in the case of certain
regimens of chemotherapy and, especially, of hyperthermia,
contrary effects were observed (for an overview see Steen,
1989). The PMEs as precursors of cell membrane phospho-
lipid synthesis generally showed a decline following chemo-
therapy (Lutz et al., 1988; Daly et al., 1990). However, to our
knowledge, only Evelhoch and coworkers (1987) investigated
whether these changes are response-specific markers indicat-
ing significant tumour regression following chemotherapy or
whether they are related to an unspecific action of chemo-
therapy, occurring independently of drug cytotoxicity. They
studied the in vivo response of a mammary adenocarcinoma
sensitive to adriamycin in comparison to a drug-resistant
subline following treatment with adriamycin by 31P NMR
spectroscopy. As they could not find any changes in the
phosphorus metabolism in the resistant subline following
chemotherapy, the 31P NMR spectroscopic effects observed in
the sensitive subline were assigned as response-specific
markers for chemotherapy. Moreover, Cohen et al. (1986)
reported differences in the levels ofphospholipids and PCr in
a MCF-7 mammary carcinoma cell line resistant to adriamycin
in comparison to the sensitive wild type. This result was
confirmed in Evelhoch's study (1987) in the case of the
phospholipids.
Squamous cell carcinomas of the head and neck are in
advanced stage in about 60% of the patients at time of
diagnosis. Thus, they can often be treated only by X-
irradiation or chemotherapy. One of the most efficient
antitumour agents is given today by CDDP. However, only
about 14% to 26% of the tumours show complete response
following combination therapy with CDDP and 5-
fluorouracil (Posner et al., 1984; Toohill et al., 1987).
In the present study we investigated the phosphorus
metabolism, by 31P NMR spectroscopy, in a xenografted
human epidermoid carcinoma of the hypopharynx, growing
subcutaneously in athymic mice, and in two sublines of the
tumour with an increasing resistance to CDDP. In contrast
to the above mentioned studies, the sublines exhibited only
partial resistance to CDDP, which is closer to the situation
observed in human patient tumours. By comparing three
tumour lines with continuously decreasing sensitivity to
CDDP, we expected to be able to assign the phenomena
related to drug resistance regarding the initial levels of the
phosphorus containing metabolites in the tumours and the
alterations induced by CDDP with regard to the therapeutic
efficacy. Parallel to NMR spectroscopy, tumour cytokinetics
and histology were investigated in order to relate the changes
observed in the 31P NMR spectra with generally accepted
indicators of tumour response.
Materials and methods
Tumour system and chemotherapy
The investigations were performed on a moderately
differentiated carcinoma of the hypopharynx which had been
established from an untreated patient. The tumour was trans-
planted serially in male athymic mice (NMRI, nu/nu) and
passaged by implanting tumour suspensions into the flank of
the animals. From this tumour which was highly sensitive to
cisplatin (CDDP), two sublines with an increasing degree of
resistance to the drug were selected experimentally in vivo by
repeated course treatment with CDDP over several genera-
tions. The subline with the lower resistance was maintained
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by i.p. injections of 3.5 mg CDDP kg-' weekly, whilst the
animals bearing the higher resistant subline received applica-
tions of 5.5 mg CDDP kg-' twice a week. CDDP was
obtained from Strem Chemicals. Before administration, the
drug was dissolved in a mixture of DMSO and saline (1/9,
v/v). For NMR experiments, the mice of the treatment groups
obtained intraperitoneal injections of CDDP in doses of 4, 8
or 12 mg kg-' (0.1 ml solution 10 g-' body weight) whereas
the control animals only received the vehicle medium of
0.3 ml saline containing 10% DMSO. When entered to the
study the mice had an average body weight of 31.2 ± 1.5 g.
Tumour volumes were estimated by caliper measurement
according to the formula for the volume of ellipsoids
(0.5 x length x width2).
The surviving fraction of tumour cells following
chemotherapy treatment was calculated according to the for-
mula (Corbett & Valeriote, 1987):
loglO(surviving fraction) =
(growth delay) x (3.32 x tumour volume doubling time)'
NMR spectroscopy
For in vivo NMR measurements, the mice were anesthetised
by low doses of a mixture ofValium and Hypnorm (5 mgkg-'
fluanison, 0.1 mgkg-' fentanyl base, and 5 mg diazepam
kg- i.p.). 3'P NMR spectra were obtained with a Bruker
Biospec (2.35 T/40-cm horizontal-bore). Home-built probes
with a three-turn surface coil (13 mm diameter), doubly tuned
to 3'P and 'H were used for the experiments. Tumour spectra
were obtained by placing the coil on the tumour. By measur-
ing mice without a tumour and being positioned in the probe
in the same manner as with mice bearing solid, subcutaneously
growing tumours of approximately 0.8 cm3 volume, it was
ascertained that the underlying tissues did not contribute to
the tumour spectrum. The average pretreatment tumour
volume was 2.22 ± 0.41 cm3. By taking tumour spectra at 0,
24, 72, 120, 168 and 240 h after chemotherapy, a good assess-
ment of the time course of the relative concentrations of the
phosphorus-containing metabolites in the tumour was possible.
The 31P NMR spectral parameters were a resonance frequency
of 40.63 MHz, a 500 flip angle, 4 kHz bandwidth, 1 K data
points, 2 s recycle time, 750 scans. No corrections were applied
for saturation effects as these effects were negligible for NTP
and small for PME, Pi and PCr. Each free induction decay
was processed by 20 Hz line broadening. The strong overlap of
the resonances downfield of PCr caused irreproducible results
when curve fitting routines were employed for spectral
analysis. Peak heights were reproducible with less than 5%
variation and, thus, were used for spectral analysis. The
tumour pH was calculated from the chemical shift of Pi
according to Seo et al. (1983).
pH = 6.75 + log ((ppmpi - 3.15) x (5.65 - ppmpi')
To make sure that the pH obtained by this method is not
influenced by the relative heights of peaks on either side of
the Pi resonance, the PME/PDE ratios of the individual
untreated tumours were correlated with the chemical shift of
Pi. This test proved negative.
For statistical analysis the two-tailed paired t-test was
applied when tumours within one treatment group were com-
pared, whilst for comparison of the metabolite concentra-
tions of the different tumour lines, the two-tailed Student's
t-test was employed.
Morphology andflow cytometry
Parallel to the NMR experiments, morphological and cyto-
kinetic investigations were performed. For these purposes,
groups of nude mice with size-matched tumours of the three
tumour lines were treated with CDDP in doses of 4, 8 or
12mgkg-'. From these groups, one animal each was sacri-
ficed at intervals corresponding to the time points of the
NMR measurements (e.g. 0, 24, 72 h etc.). Immediately
thereafter, the tumours were removed and cut into two
pieces, one of them being destinated for morphological in-
vestigations. These specimens were immersed in a fixative
solution containing 3% glutaraldehyde and 3% paraformal-
dehyde in cacodylate buffer (pH 7.2) for 2 to 24 h, postfixed
in a 1% solution ofosmium tetroxide in cacodylate buffer for
1 h, dehydrated in the alcohol series, and embedded in Epon.
Tumours of animals which has received the carrier medium
only were handled in the same manner. Semi-thick sections
with a thickness of 0.8 to 1 iLm were prepared, mounted and
stained with toluidine blue. For electronmicroscopical pur-
poses, ultrathin sections were cut, mounted on copper grids
and contrasted with 1% aqueous solutions of uranyl acetate
and lead citrate.
The other halves of the divided tumours which had been
removed at certain intervals after application of CDDP or
the vehicle medium only were prepared for flow cytometry.
These tumour specimens were gathered and frozen in liquid
nitrogen for 1 to 30 days. Following defrosting, the tumours
were minced mechanically and enzymatically in a pepsin-
hydrochloride solution (0.2% HC1, 3,500 U 1- pepsin) for
8 min at 37C. The cell suspensions were then centrifuged at
1,300 r.p.m. for 8 min and resuspended in 70% ethanol.
After another centrifugation, the pellets were resuspended in
a solution containing 10 mg 1' ethidium bromide and 10 mM
MgCl2 in 0.1 M tris buffer (pH 7.5) in such a manner that
final concentrations of 1-2 x 106 cells per ml were attained.
To eliminate unspecific staining reactions due to RNA, the
cell suspensions were incubated with ribonuclease, added in a
final concentration of 10 gml', for 30min at 30°C. The
flow-cytometric measurements were performed with an Epics
752 cytometer (Coulter Electronics Co.) equipped with an
argon laser (wavelength 488 nm).
Results
Tumour strains
Though the resistant strains Hyp 1/H and Hyp I/R represent
sublines of the CDDP-sensitive Hypl, they all differ from
one another in many respects. The doubling time of tumour
volume amounted to 13 days in Hyp 1, 10 days in Hypl/H,
and 8 days in Hyp I/R. Moreover, the tumours were charac-
terised by different histological patterns. Whereas the
tumours of the original sensitive strain Hyp 1 consisted of
tumour cell clusters with a broad peripheral border of
densely packed, viable cells and small central areas filled up
with necrotic cells, the tumour cell border was loosened in
the moderately and highly resistant strains Hyp 1/H and Hyp
I/R, included numerous enlarged extracellular spaces, and
consisted of reticularly arranged tumour cell cords (Figures
5a, 6a). Only in large resistant tumours, centrally located
necroses were detectable. Small, capillary-conducting strands
of connective tissue surrounded the tumour cell aggregates,
being separated from them by a basal lamina which was
often multilayered in the sensitive tumour line Hyp 1, but
monolayered in both resistant strains. In all three tumour
lines, the tumour cells were large, roundish cells with a clear
nucleus including a prominent, compact nucleolus and a
cytoplasm with numerous ribosomes, but few other
organelles (Figure 7a,b).
Figure 1 illustrates an example of a 3'P NMR spectrum of
an individual Hyp 1 tumour. The average metabolic charac-
teristics and the tumour volumes of the three tumour lines
before substance application are given in Table I (the data
presented include both treatment and control groups). The
semi-resistant strain Hyp 1/H differed from the drug-sensitive
Hyp 1 with regard to the PME/a-NTP and P-NTP/a-NTP
ratios with a confidence value of P <0.05. The highly resist-
ant strain Hyp 1/R, however, did not show any statistically
significant differences from Hyp 1.
Uninfluenced tumour growth
Figures 2-4 show the changes occurring in the metabolite
ratios PCr/Pi and PME/PDE and the pH of the three tumour31P NMR SPECTROSCOPY OF THREE SUBLINES OF A XENOGRAFTED CARCINOMA 487
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Figure 1 Typical in vivo 31P NMR spectrum of an individual
hypopharynx carcinoma sensitive to CDDP (Hyp 1) on day 32
after implantation. Peak A - PME; B - Pi; C - PDE; PCr; E - y
- ATP; F - ax-ATP; G - P-ATP.
strains on days 3 and 10 after treatment with different doses
of CDDP (0, 4, 8 o 12 mg CDDP kg-') together with the
tumour growth curves during an interval of 10 days after
drug application. The metabolite ratios are related to the
pretreatment value whereas the pH change is given as actual
number. The pretreatment tumour volumes were always nor-
malised to 1. During uninfluenced tumour growth (0 mg
CDDP kg-'), all three tumour lines showed similar changes
in the 31P NMR spectra. Moderate decreases in the PCr/Pi
ratio (P <0.01, change from day 0 to day 16 for Hyp 1,
n = 8) and the P-NTP/a-NTP quotient (P <0.05) occurred,
indicating a decline in the energy level of the tumours.
Moreover, parallel increases in the PDE/a-NTP (P <0.01)
and PME/a-NTP levels were observed, resulting in a nearly
constant value of the PME/PDE ratio (Figures 2-4, b and
c). The tumour pH did not show any change. The only
alteration observable in tumour morphology during uninflu-
enced growth was the increase or appearance of central
necroses in all tumour strains.
Reactions ofthe tumour strains to CDDP
CDDP-sensitive strain Hyp I The changes in the tumour
volume of Hyp 1 following administration of CDDP (4, 8 or
12 mg kg-') were characterised by a clear dependence on the
dose applied (Figure 2a), the growth delay amounting to 26
days in the high dose group. Figure 2b and c illustrates the
alterations occurring in the main metabolic parameters of the
31P NMR spectrum, i.e., the ratios PME/PDE and PCr/Pi
and the pH value, on days 3 and 10 after administration of4,
8 or 12mg CDDP kg-'. Within 3 days after application of
CDDP, the tumour pH shifted to the alkaline by 0.4 units
after application of 12 mg CDDP kg-I (P <0.001, n = 15),
whereas no significant change could be observed following
treatment with the other doses. On the other hand, the
decrease in the PME/PDE level, determined on day 3,
showed a clear dose dependence (P <0.001 for 8 and 12 mg
CDDP kg-', P<0.01 for 4mg CDDP kg-') and was
mainly due to a decrease in the PME level. Between days 3
and 10, the PME/PDE ratio hardly changed in the 4 and
12 mgkg-' dose groups, but increased in the 8 mg kg-' dose
group. The PCr/Pi value, finally, increased continuously from
day 1 to 10 without any marked difference between the three
treatment groups. Because of the large variance of this
change, the confidence value only amounted to P <0.01 on
day 3 after treatment in all three groups.
These pronounced changes of the 31P NMR-spectral para-
meters were accompanied by severe morphological and cyto-
kinetic alterations. In all dose groups, the first morphological
alteration observable on day 1 was a remarkable dilation of
the capillaries within the strands of connective tissue. A
CDDP dose of 4 mg kg-' was sufficient to induce necrotisa-
tion of many tumour cells within 3 to 6 days resulting in a
loosening of the peripheral border of the tumour cell clusters,
the appearance of enlarged intercellular spaces and the in-
crease of central areas filled up with necrotic tumour cells.
On days 6 to 9, the layers of vital tumour cells had become
markedly smaller and discontinuous. First signs of recovery
were detactable on days 9 and 10. The DNA histograms
revealed the arrest of many tumour cells in the S phase on
days 2 and 3 after application of the low CDDP dose (data
not shown). When the higher doses of 8 and 12 mg CDDP
kg-l were administered, similar histological and cytokinetic
phenomena developed, whereby the strength of the symp-
toms, the moment of their appearance and the reversibility
were clearly dose-dependent. Following treatment with
12 mg kg-', most tumour cells became necrotic within 3 days
resulting in a nearly complete destruction of the original
tumour tissue between days 3 to 15. Thereafter, recovery
occurred and led to the reconstruction of tumour tissue
within several days.
Moderately resistant strain Hyp l/H
Compared to the wild type Hyp 1, the partially resistant
strain Hyp 1/H was characterised by clearly decreased sen-
sitivity to CDDP. Whereas a dose of 4 mg CDDP kg-' was
not able to induce any growth delay (Figure 3a) doses of 8
and 12 mg CDDP kg-' effected marked tumour regression,
but regrowth occurred on day 7 after chemotherapy. During
the first 3 days after treatment with 8 and 12 mg CDDP
kg-1, the metabolic alterations in Hyp 1/H tumours showed
the same trends as in Hyp 1, the extent of the changes being
clearly less pronounced (Figure 3b,c) than in Hyp 1 (Figure
Table I In vivo pretreatment values of metabolite ratios, pH, and tumour size in the
three tumour lines investigated
Metabolite
PME/a-NTP
PDE/ax-NTP
Pi/a-NTP
PCr/a-NTP
P-NTP/a-NTP
pH
Tumour volume (cm3)
Hyp I (n = 39) Hyp 1/H (n = 23) Hyp 1/R (n = 32)
1.22 (0.23) 1.35 (0.21)a 1.26 (0.19)
0.97 (0.17) 1.04 (0.18) 0.99 (0.16)
1.02 (0.19) 1.06 (0.21) 1.07 (0.16)
0.81 (0.17) 0.89 (0.19) 0.83 (0.17)
0.63 (0.11) 0.70 (0.13)a 0.65 (0.08)
6.97 (0.16) 7.04 (0.14) 6.94 (0.20)
2.22 (0.47) 2.37 (0.51) 2.07 (0.35)
The values given are the means of the parameters evaluated in the number of animals
indicated at the top. The standard deviations are added in parenthesis. ap<0.05 as
compared to Hyp 1.488 R. TAUSCH-TREML et al.
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Figures 2-4 Growth curves a, metabolite ratios and pH-change 3, b, and 10 days c, after application of 0, 4, 8 or 12 mg
CDDP/kg-'. The metabolite ratios are referenced to the pretreatment level whereas the pH change is given as actual number. The
bars indicate the SD-values.
Figure 2 Sensitive strain Hyp 1 (number of animals; 0mg kg-1: n = 8; 4 mg kg-1: n = 6; 8 mg kg-1: n = 10; 12 mg kg-1: n = 15).
Figure 3 Moderately resistant strain Hyp 1/H (number of animals; 0mg kg-'; n = 6; 4mg kg-': n = 5; 8mg kg-': n = 6;
12 mg kg-': n = 6).
Figure 4 Highly resistant strain Hyp I/R (number of animals; 0 mg kg-': n = 7; 4 mg kg-': n = 6; 8 mg kg-': n = 6; 12 mg kg-':
n = 13).
Legend for a: - 0mg CDDP kg-', -- 4 mg CDDP kg- ,. 8 mg CDDP kg-',--- 12 mg CDDP kg
Legend for b and c: - pH-change, PME/PDE, - PCr/Pi.
2b,c). The pH increased by 0.15 units after 12 mg CDDP
kg-', this alteration, however, being not significant (n = 6).
In contrast to the metabolic changes observable in Hyp 1, the
PME/PDE value markedly increased in the 12 mg kg-' treat-
ment group between days 3 and 10 after treatment. The
non-responsive group, treated with 4 mg CDDP kg-', finally,
showed changes similar to those observable in untreated
tumours.
Morphologically, no remarkable alterations were detect-
able in histological and semi-thick sections of the semiresist-
ant strain following application of 4 mg CDDP kg-' (Figure
Sb). Only at the ultrastructural level, many nucleoli appeared
loosened and showed the signs of gradual segregation of the
nucleolar components between days 2 to 10 (Figure 7,c,d). In
the case of the medium dose of 8 mg CDDP kg-', the
histological and electronmicroscopical specimens revealed
necrotisaton of single cells or cell groups within the
peripheral border of vital tumour cells on day 3 (Figure 7c).
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Figure 5 Semi-thick sections of the moderately resistant xeno-
grafted hypopharynx carcinoma strain Hyp 1/H. a, Untreated
tumour, consisting of clusters of reticularly arranged tumour cell
cords, encircling wide extracellular spaces. The clusters are sur-
rounded by strands of connective tissue. b, Hyp I/H, 3 days after
application of 4 mg CDDP kg-'. No alterations are detectable in
relation to the untreated tumour. Note the numerous mitotic
figures. c, Hyp 1/H, 3 days after application of 8 mg CDDP kg-'.
Numerous tumour cells show the signs of cellular necrotisation,
manifesting by chromatin clumping and the appearance of cyto-
plasmic inclusion bodies. The extracellular spaces are widened in
comparison to the controls. d, Hyp 1/H, 3 days after 12mg
CDDP kg-'. The tumour cell border is markedly attenuated,
includes some necroses and is loosened by widened extracellular
spaces. Compensatorily, the area of central necroses is enlarged.
x 225 a,b, x 450 c,d.
This development manifested by the condensation of the
nucleolar chromatin, segmentation of the nuclei, segregation
of the nucleolar components, and the appearance of large
secondary lysosomes and glycogen inclusions in the cyto-
plasm between days 2 to 6. The tumour tissue loosened as
consequence of the enlargement of intercellular spaces. From
day 1 after substance application, the capillaries in the
strands of connective tissue were widened and filled with
crowds of blood cells. Beginning on day 6, the number of
structurally damaged and necrotic cells again decreased and
normal morphology restored by day 8. When the highest
dose of 12 mg CDDP kg-' was administered to the animals
bearing Hyp 1/H, the mentioned cytological and histological
alterations developed in the tumours more rapidly and more
severely. On day 3, only plaque-like residues of comparably
intact tumour tissue were detectable (Figue 5a). macrophages
had invaded the xenografts and phagocytosed necrotic
tumour cells. On day 6, first signs of ongoing recovery were
remarkable leading to a gradual reconstruction of tumour
cell clusters with only small areas of central necrosis during
the following 4 days.
A similar dose dependence also manifested in the DNA
histograms of the Hyp 1/H tumours. When they were treated
with 4 mg CDDP kg-', no pronounced cell cycle alterations
were observable (Figure 8). Following application of the
highest dose of 12 mg CDDP kg-', a remarkable portion of
cells were arrested at the G0/S boundary during the first 3
days, then traversed through the S phase on days 4 and 5
and reached the G2 phase on day 6, provoking there a
pronounced G2 block which continuously dissolved during
the following 2 days. Additionally, numerous cells were
highly damaged on day 3 and disintegrated to cellular and
nuclear fragments which appeared in the histograms at low
DNA values as a peak increasing exponentially to zero.
Moreover, a third symmetrical peak grew up on the left of
the G0 population of the tumour cells (Figure 8). This peak
represents mouse connective tissue cells such as macrophages
and fibroblasts, which immigrated into the xenografts of
human tumours, differing from human tumour cells by a
lower DNA content and a lower number of chromosomes.
All these phenomena were reversible within several days, thus
leading to a normalisation of the histograms on day 10. In
the case of the medium dose of 8 mg CDDP kg-', a
moderate cell arrest in the early S phase developed within
1 day. This cell population progressed synchronously through
the mid and the late S phase during the following 48 h, and
attained the G2 phase on day 5 and induced there a moderate
G2 block on days 5 and 6, which gradually dissolved within
the following 2 days (data not shown).
Highly resistant strain Hyp J/R
In the resistant tumour line Hyp 1/R, finally, the lower
CDDP doses (4 and 8 mg kg-') did not effect any significant
retardation of tumour growth, whereas 12 mg CDDP kg-'
induced a growth delay of 5 days, however, without causing
mentionable reduction of the tumour volume (Figure 4a).
Accordingly, no significant metabolic changes occurred in the
31P NMR spectrum with none of the CDDP doses applied.
Only in the case of the high CDDP dose, the data on day 3
indicate a trend (Figure 4b) similar to that seen in the
responsive tumours of Hyp 1 (Figure 2b) and Hyp 1/H
(Figure 3b). When tumour regrowth happened on day 5 and
later, the metabolic alterations which developed were com-
parable to those observed in tumours during uninfluenced
growth (Figure 4c). In the Hyp I/R tumours treated with 4
or 8 mg CDDP kg-' the changes in metabolism paralleled
those of the untreated tumour during the whole post-
therapeutic period (Figure 4b,c).
Regarding the morphological alterations, no effects were
detectable in the Hyp 1/R tumours following application of
4 mg CDDP kg-' (Figure 6b). In the case of 8 mg CDDP
kg-' (Figure 6c), only single tumour cell necroses occurred
sporadically in the peripheral areas of the tumour clusters on
days 2 to 6. Augmenting the dose to 12 mgkg-', the number490 R. TAUSCH-TREML et al.
Figure 6 Semi-thick sections of the highly resistant xenografted
hypopharynx carcinoma strain Hyp I/R a, untreated tumour,
built up by polygonal tumour cells, constituting a tissue resemb-
ling the epidermoid spinous layer and including enlarged extracel-
lular spaces. It is encircled by small strands of connective tissue,
b, 3 days after treatment with 4 mg CDDP kg-'. No changes in
comparison to the control tumour, a,c, 3 days after 8 mg CDDP
kg-'. Only single tumour cell necroses are detectable in the
tumour tissue, d, 3 days after 12mg CDDP kg-'. Disseminated
tumour cell necroses and widened extracellular spaces are con-
spicuous findings. x 450 a,c,d, x 360 b.
Figure 7 Electron-microscopical sections ofthe moderately resis-
tant xenografted hypopharynx carcinoma strain Hyp 1/H. a,
Control tumour, being composed of large tumour cells with clear
nuclei and compact nucleolii. b, Control tumour at higher
magnification, showing a reticular, but compact appearance of
the nuclear nucleoli. c, Beginning segregation of the nucleolar
components on day 4 after application of 4mg CDDP kg-'. d,
Progressed segregation phenomenon within tumour cell nucleoli
on day 11 after treatment with 4mg CDDP kg-'. x 5,000. a,
x 13,000; b, x 14,000; c, x 10,500 d.
... ... - -----
.0
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Figure 8 DNA distribution curves of the moderately resistant hypopharynx carcinoma Hyp 1/H following application of 4 mg
CDDP kg-' (on the left) and 12 mg CDDP kg-' (on the right). C, untreated control. Substance application at time 0. The black
colour marks peculiar features developing under the influence of CDDP.
of developing tumour cell necroses slightly increased on days
2 to 6 after application of CDDP (Figure 6d), the strength of
structural damages resembling those of Hyp 1/H tumours
after treatment with 8 mg CDDP kg-'. On day 8 and later,
the Hyp I/R tumours had again normalised and no longer
showed any peculiar features in comparison to untreated
control tumours. In correspondence to these morphological
results, the cytokinetic investigations confirmed that neither
4 nor 8 mg CDDP kg-' were able to disturb the cell progres-
sion. In the case of the highest dose of 12 mgkg-' a G2
block appeared 4 days after substance application as the only
observable finding.
Discussion
Cohen and coworkers (1986) were the first investigators who
reported on differences in the levels of phosphate metabolites
in a MCF-7 mammary carcinoma cell line resistant to
adriamycin in comparison to the corresponding sensitive
tumour cell line. In the latter, the relative spectral conribu-
tion of phosphocreatine was reduced, whereas the concentra-
tions of the PME and PDE were elevated. Evelhoch et al.
(1987) confirmed these results in a 3'P NMR study for the
phospholipids in the murine mammary adenocarcinoma
Mamm 17/A sensitive to adriamycin and the resistant subline
Mamm 17/Adr growing in C3H/He mice. In the present
study on the Hyp 1 squamous cell carcinoma, which was
highly sensitive to CDDP, and its sublines Hyp 1/H and Hyp
1/R, which were characterised by increasing levels of resist-
ance to CDDP, these results could not be verified, Hyp 1/H
contained higher levels of PCr and PME than Hyp 1, but the
confidence values of these differences were low (Table I). Hyp
1/R which was more resistant to CDDP than Hyp 1/H, did
not show analogous differences. As CDDP exerts its cytoxi-
city by producing intrastrand crosslinks in DNA strands
(Sundquist & Lippard, 1990), whilst adriamycin intercalates
between neighbouring DNA bases (Muller, 1975), the
mechanisms of induced drug resistance are different. In the
case of CDDP increased resistance of tumour cells was
shown to result often from a higher cellular efficiency in
excising Pt-DNA adducts (Masuda et al., 1988, Eastman &
Schulte, 1988; Sekiya et al., 1989), whereas in cells resistant
to adriamycin an enhanced capacity for drug transport out of
the cells was supposed to be the main mechanism responsible
for drug resistance (Inaka et al., 1979; Cowan et al., 1986). it
is conceivable that this property of adriamycin-resistant cells
is associated with alterations in membrane metabolism and,
thus, could explain the decreased concentrations of the PMEs
and PDEs, which are both metabolites of membrane-bound
phospholipids (for an overview see Van den Bosch, 1974;
Cohen, 1988).
In a '3C NMR study, Lyon et al. (1988) found that the
adriamycin-resistant MCF-7 cancer cell line had developed
an enhanced glycolysis rate compared to the sensitive cell
line. This was explained by increased energy requirement
associated with drug efflux and detoxification and would be
consistent with the finding of a higher PCr level in the
adriamycin-resistant cell line. However, neither in Evelhoch's
investigations (1987) nor in the present study, this result
could be confirmed for the resistant tumour lines. It is known
that, in murine and xenotransplanted tumours, the PCr ratio
is especially sensitive to the histological architecture of the
tumour (Evelhoch et al., 1986; Vaupel et al., 1989), thus
possibly obscuring differences in the energy demand of a
tumour on the cellular level. This explanation is additionally
confirmed by the observation that the resistant sublines of
Hyp 1 used in the present study actually differed in their
histological appearance from the original sensitive tumour.
Regarding the 3'P NMR spectral changes in the tumour
lines following chemotherapy with CDDP, the results
obtained indicate that the most sensitive and earliest marker
predictive for tumour response is the PME/PDE ratio. The
decrease in the level of this ratio is mainly due to a decrease
in the PME level. In tumours the main contribution to this
resonance comes from the phospholipids phosphory-
lethanolamine and phosphorylcholine (Cohen et al., 1986).
They are synthesised by the enzymatic activity of
ethanolamine and choline kinases which catalise the first step
of phospholipid biosynthesis in vivo (Van den Bosch, 1974).
Increased levels of PMEs have been hypothesised to be
associated with intensified cell membrane synthesis and cell
proliferation (Maris et al., 1985; Sostman et al., 1988). The
decline in the PME contents after therapy in the well respond-
ing tumours confirms this hypothesis.
A re-energisation occurred in responding tumours, which
was reflected by an elevation of the PCr/Pi ratio. This in-
crease was mainly due to an elevated PCr concentration in
the tumour. It is unlikely, however, that this phenomenon
would be the result of an increased signal contribution from
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the body wall because the volume of the tumours hardly
decreased during the first 3 days after substance application.
In addition, the pH increased, this change being statis-
tically significant only in the sensitive tumour line Hyp 1
after application ofthe high dose of CDDP. The extent of all
alterations were clearly related to the degree of tumour re-
sponse documented by regressions of the tumour volume and
severe cytotoxic lesions in the tumour tissue. Thus, they
provide response-specific markers of sensitivity to CDDP and
do obviously not represent effects of CDDP on tumour
metabolism which are not related to the cytotoxicity of the
drug. This result is confirmed by the fact that, in the sensitive
tumour Hyp 1, a dose of 4mg CDDP kg-', resulting in a
growth delay of about 20 days, induced more pronounced
changes in the 31P NMR spectrum than a dose of 12 mg
CDDP kg-' in the highly resistant strain Hyp I/R (growth
delay only 5 days). Sijens et al. (1987) reported an alkaline
shift in a immunocytoma resistant to CDDP following appli-
cation of a subtherapeutic dose of 1 mg CDDP kg-'. The
mechanism inducing the pH change in this tumour does
apparently not work in the epidermoid carcinoma sublines
Hyp 1/H and Hyp 1/R, where the comparably high dose of
12 mg CDDP kg-' did not provoke any effect on the pH
level.
According to the equation given by Corbett and Valeriote
(1987) (cf. Materials and methods), a dose of 12 mg CDDP
kg-' would induce a cell killing of 25% cells in the highly
resistant strain Hyp 1/R, 62% in the semiresistant line Hyp
1/H, and 78% in the sensitive strain Hyp 1. This means that
the 31P NMR spectroscopy would be insensitive to rates of
cell killing at the level of 30%. Regarding the histological
sections, however, they did not confirm the development of
substantial cellular necroses in Hyp I/R tumours following
treatment with 12 mg CDDP kg-'. That is to say that, in the
case of CDDP doses which only induce short-lasting growth
delays, but no tumour regression, the formula for the estima-
tion of cell killing obviously leads to wrong results.
The only cytokinetic phenomenon observed in Hyp I/R
tumours was a G2 block, which dissolved on days 4 to 5 after
chemotherapy, allowing the cells to restart proliferation. In
contrast, treatment of the Hyp 1/H and Hyp 1 strains with
12 mg CDDP kg-' primarily resulted in a cell arrest at the
GI/S boundary which was clearly associated with severe
cytoxicity at the histological level (Jiickel & K6pf-Maier,
1990). As this block dissolved earlier in the semi-resistant
tumour Hyp 1/H, the cells reached the G2 and M phases
sooner than in the sensitive wild type. As a consequence,
tumour regrowth occurred earlier in Hyp 1/H than in Hyp 1
(Figures 2a and 3a). This process was accompanied by an
increase of the PME/PDE ratio on day 10 in Hyp 1/H
compared to day 3 (Figure 3b,c). This increase was mainly
due to an elevated PME concentration in the tumour, render-
ing this metabolite to be a sensitive marker of both tumour
regression and tumour regrowth.
The histological sections revealed widened capillaries on
day 1 after chemotherapy and enlarged extracellular spaces in
responding tumours, the first necrotic cells being detectable
on day 3 after chemotherapy. In accordance with the 31P
NMR-spectral changes, these alterations were more pro-
nounced in the sensitive tumour Hyp 1 than in the semi-resist-
ant Hyp 1/H or in the highly resistant Hyp I/R. Following
application of CDDP doses which hardly induced any
growth delay of the treated tumours (4 mg CDDP kg-' in
Hyp 1/R and Hyp 1/H), the histological and semi-thick sec-
tions did not reveal any morphological changes. Ultrastruc-
turally, however the nucleoli within these tumours appeared
loosened and showed the signs of segregation of the nucleolar
components. Interestingly, these phenomena did not exhibit
any detectable changes in the 31P NMR spectrum.
Summarising the histological and cytokinetic data, they
provide evidence that actually only those tumour cell altera-
tions, which are related to cytotoxic effects and finally cul-
minate in tumour cell dying, are correlated with profound
metabolic changes observable in the phosphorus NMR.
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